阿斯利康的争议事件

来源摘录

• IFC has filed a defence against the allegations. Their filing calls AstraZeneca’s claim “misconceived and incorrect”.

• The pharmaceutical giant has accused International Fire Consultants (IFC) of causing “widespread defects” in the construction of its Cambridge-based facility,

• AstraZeneca stated that, between 2021 and 2023, the remediation work they carried out to address the defects cost them over £31.7 million.

品牌回应

• 否认 — 阿斯利康

  我们相信（欧盟的）任何诉讼都没有法律依据

来源摘录

• 我们相信（欧盟的）任何诉讼都没有法律依据

• 阿斯利康发表声明回应，称对欧盟这项行动表示遗憾，将在法庭申辩。

品牌回应

• 否认 — AstraZeneca

  AstraZeneca shortly struck back, claiming it had fully complied with the advance purchase deal with the European Commission, and adding it was set to strongly defend itself in court.

来源摘录

• AstraZeneca shortly struck back, claiming it had fully complied with the advance purchase deal with the European Commission, and adding it was set to strongly defend itself in court.

• The European Union has kicked off legal proceedings against the Swedish-British pharmaceutical company AstraZeneca citing its failure to deliver on an agreed upon contract to deliver vaccines to EU countries, the European Commission said in a statement.

• Wednesday, 5 May 2021, 4:40 pm

来源摘录

• The plaintiff stated that contrary to the claims made in the notice letter, the defendant’s generic version of the drug does directly infringe upon claims within its patent and its relation to their brand name drug BRILINTA.

• On Friday, pharmaceutical company AstraZeneca filed a lawsuit against Alembic Pharmaceuticals for allegedly infringing on their drug patent.

来源摘录

• The plaintiffs alleged that AstraZeneca’s Tagrisso drug, even though it was approved by the Food and Drug Administration, infringes on their patent.

• On Wednesday a case was filed in the District Court of Delaware. The case was filed by PUMA Biotechnology Inc and Wyeth LLC against AstraZeneca Pharmaceuticals.

品牌回应

• 道歉 — Daily Express

  The British tabloid apologised for the publication of the false theft claim

• 澄清 — Daily Express

  The Daily Express, a British tabloid, issued a correction to an 11 October article, which falsely claimed that "Russia [...] copied the formula of the AstraZeneca jab and used it to help make its own vaccine".

来源摘录

• The Daily Express, a British tabloid, issued a correction to an 11 October article, which falsely claimed that "Russia [...] copied the formula of the AstraZeneca jab and used it to help make its own vaccine".

• The British tabloid apologised for the publication of the false theft claim and sought to "set the record straight" by publishing the official response of the Russian Direct Investment Fund (RDIF), which funded the Sputnik V development.

来源摘录

• AstraZeneca (, AZN) filed a lawsuit in the U.K. against GlaxoSmithKline (GSK), saying a 2012 licensing agreement over the Zejula cancer drug was breached and, therefore, it should have a greater share of sales

来源摘录

• British regulators on Thursday said they have identified 30 cases of rare blood clot events after the use of the AstraZeneca Covid-19 vaccine, 25 more than the agency previously reported.

来源摘录

• The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is investigating cases of thromboembolic events related to AstraZeneca's COVID-19 vaccine, but says the benefits currently still outweigh risks.

• Experts are looking in great detail at all the available data and clinical circumstances surrounding specific cases to determine whether the vaccine might have contributed or if the event is likely to have been due to other causes.

来源摘录

• A participant information sheet dated Sept. 11 on AstraZeneca’s trial in Britain lumped the two volunteers’ cases together, stating the illnesses were “unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine,” based on safety reviews.

• AstraZeneca revealed details of its large coronavirus vaccine trials Saturday, the third in a wave of rare disclosures by drug companies under pressure to be more transparent about how they are testing products that are the world’s best hope for ending the pandemic.

来源摘录

• Despite these calls, both the FDA and AstraZeneca have yet to explain why the trial hasn't resumed.

• both the FDA and AstraZeneca should be more open about why the trial for the coronavirus vaccine remains on pause

来源摘录

• A 40-year-old volunteer for 'Covishield', the candidate vaccine being tested by the Pune-based Serum Institute of India (SII), has sued the company for ₹5 crore, alleging that the vaccine triggered an adverse reaction, which includes neurological impairment and an inability to get back to the life before being inoculated.

• The hospital's institutional ethics committee had given a letter, Dr. Ramakrishnan said, that said the adverse reaction was not due to the study vaccine, and this was also communicated to the Drug Controller General of India (DGCI), the apex regulator.